A translational view of these findings suggests that finely-tuned ADO concentrations in the BM myeloma niche (12) contribute to symptomatic MM among patients with asymptomatic monoclonal gammopathy of undetermined significance (MGUS) and with smoldering multiple myeloma (SMM) (13, 14). Here, ADO is linked to Miyoshi myopathy.